Picture of BioPorto A/S logo

BIOPOR BioPorto A/S Share Price

0.000.00%
dk flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-5.42%
3m+66.87%
6m+92.96%
1yr-1.22%
Volume Change (%)
10d/3m+36.85%
Price vs... (%)
52w High-24.16%
50d MA+25.35%
200d MA+56.71%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-76.23%
Return on Equity-88.03%
Operating Margin-282.1%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of BioPorto A/S EPS forecast chart

Profile Summary

Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
November 22nd, 1917
Public Since
January 2nd, 1985
No. of Shareholders
19,536
No. of Employees
31
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
dk flag iconOMX Nordic Exchange - Copenhagen
Shares in Issue
334,693,000

BIOPOR Share Price Performance

Latest News for BIOPOR

Upcoming Events for BIOPOR

Q4 2022 Bioporto A/S Earnings Release

Bioporto A/S Annual Shareholders Meeting

Q1 2023 Bioporto A/S Earnings Release

Similar to BIOPOR

Picture of Ambu A/S logo

Ambu A/S

dk flag iconOMX Nordic Exchange - Copenhagen

Picture of Bactiquant A/S logo

Bactiquant A/S

dk flag iconOMX Nordic Exchange - Copenhagen

Picture of Coloplast A/S logo

Coloplast A/S

dk flag iconOMX Nordic Exchange - Copenhagen

Picture of Demant A/S logo

Demant A/S

dk flag iconOMX Nordic Exchange - Copenhagen

Picture of GN Store Nord A/S logo

GN Store Nord A/S

dk flag iconOMX Nordic Exchange - Copenhagen

FAQ

Or unlock with your email

Or unlock with your email